OBJECTIVE: To determine the clinical importance of anticardiolipin (aCL), anti-beta(2)-glycoprotein I (a beta(2)-GPI), antiprothrombin (aPT), and lupus anticoagulant (LAC) antibodies in patients with systemic lupus erythematosis (SLE) with and without a history of thrombosis. METHODS: We studied 100 patients with SLE (32 with a history of thrombosis), 27 patients with a lupus-like disease (9 with a history of thrombosis), and 41 healthy volunteers, IgG and IgM aCL, antibodies to the protein cofactors (a beta(2)-GPI and aPT) were determined by ELISA. Eighty-six of 127 patients were also tested for LAC. RESULTS: IgG aCL and LAC were associated with thrombosis but sensitivity (63 and 61%) and specificity (66 and 66%, respectively) of these tests were low. IgG and IgM a beta(2)-GPI were, respectively, 85 and 86% specific for a thrombotic history, but sensitivity was very low (32 and 29%). High IgG aCL were associated with the presence of a beta(2)-GPI and were 85% specific for thrombosis. There was no significant association between IgG or IgM aPT and thrombosis. CONCLUSION: Only high levels of IgG aCL and presence of LAC and/or a beta(2)-GPI are relevant in defining a thrombotic subset of patients with SLE. Longitudinal prospective studies are needed to investigate the predictive value of the different antiphospholipid and protein cofactor antibodies.
OBJECTIVE: To determine the clinical importance of anticardiolipin (aCL), anti-beta(2)-glycoprotein I (a beta(2)-GPI), antiprothrombin (aPT), and lupus anticoagulant (LAC) antibodies in patients with systemic lupus erythematosis (SLE) with and without a history of thrombosis. METHODS: We studied 100 patients with SLE (32 with a history of thrombosis), 27 patients with a lupus-like disease (9 with a history of thrombosis), and 41 healthy volunteers, IgG and IgM aCL, antibodies to the protein cofactors (a beta(2)-GPI and aPT) were determined by ELISA. Eighty-six of 127 patients were also tested for LAC. RESULTS: IgG aCL and LAC were associated with thrombosis but sensitivity (63 and 61%) and specificity (66 and 66%, respectively) of these tests were low. IgG and IgM a beta(2)-GPI were, respectively, 85 and 86% specific for a thrombotic history, but sensitivity was very low (32 and 29%). High IgG aCL were associated with the presence of a beta(2)-GPI and were 85% specific for thrombosis. There was no significant association between IgG or IgM aPT and thrombosis. CONCLUSION: Only high levels of IgG aCL and presence of LAC and/or a beta(2)-GPI are relevant in defining a thrombotic subset of patients with SLE. Longitudinal prospective studies are needed to investigate the predictive value of the different antiphospholipid and protein cofactor antibodies.
Authors: N Di Simone; P L Meroni; N de Papa; E Raschi; D Caliandro; C S De Carolis; M A Khamashta; T Atsumi; G R Hughes; G Balestrieri; A Tincani; P Casali; A Caruso Journal: Arthritis Rheum Date: 2000-01
Authors: Kamil Bugała; Adam Mazurek; Krzysztof Gryga; Monika Komar; Grzegorz Kopeć; Jacek Musiał; Piotr Podolec; Carlo Perricone; Wojciech Płazak Journal: Clin Rheumatol Date: 2018-04-20 Impact factor: 2.980
Authors: G Lakos; E Kiss; N Regëczy; P Tarján; P Soltész; M Zeher; E Bodolay; S Szakony; S Sipka; G Szegedi Journal: Clin Exp Immunol Date: 1999-09 Impact factor: 4.330
Authors: Wojciech Plazak; Mieczyslaw Pasowicz; Magdalena Kostkiewicz; Jakub Podolec; Lidia Tomkiewicz-Pajak; Jacek Musial; Piotr Podolec Journal: Inflamm Res Date: 2011-07-10 Impact factor: 4.575
Authors: Wojciech Plazak; Krzysztof Gryga; Hanna Dziedzic; Lidia Tomkiewicz-Pajak; Malgorzata Konieczynska; Piotr Podolec; Jacek Musial Journal: Arthritis Res Ther Date: 2011-07-20 Impact factor: 5.156
Authors: Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar Journal: J Neuroinflammation Date: 2009-01-20 Impact factor: 8.322